ReWalk is a wearable robotic exoskeleton with FDA clearance that provides powered hip and knee motion to enable individuals with spinal cord injury (SCI) to stand upright, walk, turn, and climb and descend stairs.
ReStore is a powered, lightweight soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke.
Israel
ReWalk Robotics Ltd.3 Hatnufa st. 6th fl.
P.O. Box 161,
Yokneam, 2069203
Israel
Phone: +972 4 959 0123
Email: contact@rewalk.com
Company Info
Headquarters
2001
Founded
$210M
Funding
$5.5M
Revenue
Products
ReWalk 6.0
The ReWalk Personal 6.0 Exoskeleton is a battery-powered system that provides spinal cord injury patients with the ability to stand, walk, and navigate stairs and curbs in their homes and communities. The exoskeleton is custom-configured to each user’s body to ensure optimal safety, comfort, and function.
The wearable device is self-supporting and features motors at the hip and knee joints, as well as adjustable ankle joints, enabling users to walk with a natural gait pattern. ReWalkers control the exoskeleton’s movement using buttons on their wrist and subtle trunk motion during walking. The ankle joints and software settings are highly customizable, allowing clinicians to fine-tune the gait pattern for each individual’s natural and efficient movement. The exoskeleton also includes buttons located on the hips for stair and curb navigation.
ReStore
ReStore is a lightweight, powered exo-suit that has revolutionized post-stroke gait training for individuals with lower limb disability. Its soft design incorporates natural movements with plantarflexion and dorsiflexion assistance that adapt to the patient’s gait pattern, promoting functional gait training.
ReStore’s individualized assistance levels and compatibility with supplemental support aids make it versatile and applicable for a wide range of patients undergoing gait rehabilitation. The exo-suit provides real-time feedback and adjustable assistance levels, allowing therapists to optimize sessions and track patients’ progress based on data-driven analysis.